GSE99187
In vivo response of EpCAM+ pancreatic cancer cells to gemcitabine plus anti-LIF neutralizing antibody treatment
The goal of this study is to investigate the molecular mechanisms of LIF action on pancreatic cancer cells in the classical pancreatic ductal adenocarcinoma mouse model KrasLSL-G12D;Tp53f/f;Rosa26LSL-Luc;Pdx1-Cre mice EpCAM+ pancreatic cancer cells were isolated from pancreatic tumors developped in KrasLSL-G12D;Tp53f/f;Rosa26LSL-Luc;Pdx1-Cre mice treated with either gemcitabine plus control IgG or gemcitabine plus anti-LIF antibody by FACS Overall design: The KrasLSL-G12D;Tp53f/f;Rosa26LSL-Luc;Pdx1-Cre mice at 42~43 days of age were treated with either gemcitabine plus control IgG or gemcitabine plus anti-LIF antibody for five days (50mg/kg BW gemcitabine on day 1 and day4, 25 mg/kg BW control IgG or anti-LIF mAb on day 1,3,5), and whole tumors from each treated mice were individually dissected out on day 6, dissociated into single cell suspension by enzyme digestion, and EpCAM+ pancreatic cancer cells were purified by FACS